INCB 59872

Drug Profile

INCB 59872

Alternative Names: INCB 059872; INCB-59872

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 23 May 2016 Incyte initiates enrolment in a phase I/II trial for advanced malignancies in USA (NCT02712905)
  • 01 May 2016 Phase-I/II clinical trials in Cancer (Late-stage disease) in USA (PO) (NCT02712905)
  • 14 Apr 2016 Data from preclinical studies in Acute myeloid leukaemia models presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top